# Lancaster Capital

> Lancaster Capital is a VC fund in Glasgow backing Health Care and Medical. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Glasgow, United Kingdom
- Total investments: 14
- Last investment: Nov 2021
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.lancastercapital.co.uk/

Lancaster Capital is an early stage equity investment fund based in Scotland. They invest in people with exciting ideas for new businesses. They invest alongside such people by way of equity in the companies they start up. It's the simplest of co-operations – they enable money and these exciting business ideas to come together to createsuccessful enterprises and wealth.They prefer to invest in new and protected technology which will perform some useful function. It will be important to them that the company they invest in does own that technology. Naturally, they favour new businesses with high growth potential.Lancaster Capital is a private fund and not an angel syndicate. They act however as a hub for a number of like minded private investors most of whom have had substantial success in building their own businesses. Their singular aim when investing together is to make good equity investments.

## Contacts

5 contacts available for Lancaster Capital. Shizune tracks 1 team members at Lancaster Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lancaster-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 29% |
| Medical | 2 | 14% |
| Biotechnology | 2 | 14% |
| Manufacturing | 2 | 14% |
| Telecommunications | 2 | 14% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 7 | 50% |
| Seed | 5 | 36% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 6 | 43% |
| United States | 2 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Nick Sarris | Founder & Director | 0 | https://shizune.co/investors/profile/nick-sarris-0538 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Carketa | CarKeta helps car buyers and used car dealerships connect better and faster. | $6M | Seed | Nov 16, 2021 |  |
| Skylark Lasers | Skylark Lasers specialise in the development and production of ultra-stable, spectrally pure CW single frequency DPSS lasers. Our NIR and UV lasers enable the advancement of life science, deep tech manufacturing, and quantum research. We work collaboratively with our customers and research partners to understand their needs and tailor our lasers totheir application – helping reveal the unseen, detect the imperceptible, and measure the unknown.From optomechanical design to software development, our team pushes the capabilities of laser technology to engineer ultra-stable, spectrally pure DPSS lasers. Established in 2013 with a focus on the R&D of uncommon and hard-to-reach wavelengths, we now deliver commercial systems trusted by leading researchers and OEMs worldwide.Each laser system is precision engineered under Class 5 cleanroom conditions at our headquarters in Edinburgh, Scotland. | $1.3M |  | Aug 16, 2017 |  |
| Curapel | Curapel is a privately held healthcare company that is developing innovative, safe and effective technologies for common and distressing skin conditions. We have three products in development which target eczema, psoriasis and problems of skin pigmentation. | $458K |  | May 22, 2016 |  |
| Skylark Lasers | Skylark Lasers specialise in the development and production of ultra-stable, spectrally pure CW single frequency DPSS lasers. Our NIR and UV lasers enable the advancement of life science, deep tech manufacturing, and quantum research. We work collaboratively with our customers and research partners to understand their needs and tailor our lasers totheir application – helping reveal the unseen, detect the imperceptible, and measure the unknown.From optomechanical design to software development, our team pushes the capabilities of laser technology to engineer ultra-stable, spectrally pure DPSS lasers. Established in 2013 with a focus on the R&D of uncommon and hard-to-reach wavelengths, we now deliver commercial systems trusted by leading researchers and OEMs worldwide.Each laser system is precision engineered under Class 5 cleanroom conditions at our headquarters in Edinburgh, Scotland. | $1.3M |  | May 05, 2016 |  |
| Taragenyx | A medical device company developing a broad pipeline of bio-passive, bio active and bio regenerative coatings for orthopaedic and dental implants. Taragenyx incorporate active pharmaceuticals and biologics into the coating of the implant surface itself giving the ability to release compounds locally from the implant post-operatively. Therebybringing the potential to; accelerate bone growth, drive faster healing and reduce the incidence of infection and pain. | $821K |  | Aug 14, 2015 |  |
| Sofant Technologies | Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems. | $573K |  | Mar 21, 2015 |  |
| ProFactor Pharma | Haemophilia is an X-linked genetic disease associated with the dysfunction of the biological cascade leading to blood clotting. Coagulation factors are vital to the functioning of the mechanism that the human body uses to protect and repair itself from physical injury, by the formation of blood clots to seal ruptured blood vessels. Haemophiliapatients have a reduced capacity to stop bleeding and are prone to bleeding internally, into joints and organs, and often require hospitalisation 3-4 times per year. Without proper treatment, haemophiliacs typically die from organ failure in their teens. | $120K |  | Mar 21, 2015 |  |
| ProFactor Pharma | Haemophilia is an X-linked genetic disease associated with the dysfunction of the biological cascade leading to blood clotting. Coagulation factors are vital to the functioning of the mechanism that the human body uses to protect and repair itself from physical injury, by the formation of blood clots to seal ruptured blood vessels. Haemophiliapatients have a reduced capacity to stop bleeding and are prone to bleeding internally, into joints and organs, and often require hospitalisation 3-4 times per year. Without proper treatment, haemophiliacs typically die from organ failure in their teens. | $393K |  | Jul 28, 2014 |  |
| Sofant Technologies | Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems. | $917K | Seed | Sep 14, 2013 |  |
| Waveblade | Wavecraft Ltd is a company that is owned and operated by family and friends. Their mission statement is simple. Treat others as they themselves would like to be treated. Aspire to create the best possible technologies that meet the needs of their customers while protecting the precious resource that inspires so much of their passion. | $792K |  | May 10, 2013 |  |

10 of 14 investments shown.

## Co-investors
- [Kelvin Capital](https://shizune.co/investors/profile/kelvin-capital) — VC Fund, 8 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 6 deals together
- [Old College Capital](https://shizune.co/investors/profile/old-college-capital) — VC Fund, 2 deals together
- [Coagulare Biomedica](https://shizune.co/investors/profile/coagulare-biomedica) — VC Fund, 1 deal together
- [Crosslink Capital](https://shizune.co/investors/profile/crosslink-capital) — VC Fund, 1 deal together
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Medical Investors in United Kingdom](https://shizune.co/investors/medical-investors-united-kingdom)
- [Medical VC Funds in United Kingdom](https://shizune.co/investors/medical-vc-funds-united-kingdom)

## FAQ

### What does Lancaster Capital invest in?

Lancaster Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Funding Round and Seed stage. Most of the 14 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Lancaster Capital?

Public channels for Lancaster Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Lancaster Capital?

The team at Lancaster Capital includes Nick Sarris (Founder & Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co